第一条 为规范北京义翘神州科技股份有限公司（以下简称"公司"）的关联 交易行为，保障公司及中小股东的合法权益，根据《中华人民共和国证券法》《上 市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上 市公司自律监管指引第 7 号——交易与关联交易》等法律、法规、规范性文件及 《北京义翘神州科技股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，制定本办法。 第二条 公司在处理与关联人间的关联交易时，不得损害公司及公司全体股 东特别是中小股东的合法权益。 第三条 公司关联交易应当遵循以下基本原则： （一） 符合诚实信用、平等、自愿、公平、公开、公正的原则； 北京义翘神州科技股份有限公司 关联交易管理办法 第一章 总 则 第四条 本办法所称公司关联人包括关联法人和关联自然人。 第五条 具有以下情形之一的法人或其他组织，为公司的关联法人： （一） 直接或间接控制公司的法人或其他组织； （二） 由前项所述法人直接或间接控制的除公司及其控股子公司以外的法 人或其他组织； （三） 由本办法第六条所列公司的关联自然人直接或间 ...

中信证券股份有限公司 关于北京义翘神州科技股份有限公司 2024 年度日常关联交易预计的核查意见 中信证券股份有限公司（以下简称 "保荐机构"）作为北京义翘神州科技股 份有限公司（以下简称"义翘神州"、"公司"）首次公开发行股票并在创业板上市 的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公 司自律监管指引第 13 号—保荐业务》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关规定履行持续督导职责，对义翘神州 2023 年度日常关联交易及预计 2024 年度日常关联交易事项进行了核查，核查情况及核查意见如下： 一、日常关联交易的基本情况 （一）日常关联交易概述 义翘神州根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律 法规、规范性文件及《公司章程》等相关规定，结合以前年度公司实际发生的关 联交易情况及经营发展需要，预计与关联方北京神州细胞生物技术集团股份公司 及其子公司（以下简称"神州细胞"）2024 年度发生总金额不超过人民币 ...

2023 年度财务决算报告 北京义翘神州科技股份有限公司（以下简称"公司"）2023 年度财务报表已经致同会计师 事务所（特殊普通合伙）审计，出具了标准无保留意见的审计报告。现将公司 2023 年度财务 决算情况报告如下： 北京义翘神州科技股份有限公司 一、主要会计数据和财务指标 单位：元 | 项目 | 2023 年 | 年 2022 | | 本年比 上年增 | 2021 | 年 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 减 | | | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入 | 646,388,500.38 | 574,603,390.32 | 574,603,390.32 | 12.49% | 965,272,540.65 | 965,272,540.65 | | 归属于上 | | | | | | | | 市公司股 | 260,131,747.68 | 303,134,958.32 | 302,957,765.12 | -14.14% | 720,013,671.11 | 719,905,5 ...

北京义翘神州科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范北京义翘神州科技股份有限公司（以下简称"公司"）选聘 （含续聘、改聘，下同）执行审计业务的会计师事务所的有关行为，提高财务信 息披露质量，保证公司审计工作的独立性和客观性，切实维护股东利益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市公司选聘会 计师事务所管理办法》《北京义翘神州科技股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司选 聘会计师事务所从事除财务会计报告审计之外的其他专项审计业务的，视重要性 程度可参照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会（以下简称"审计 委员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不得在董事 会、股东大会决议前聘请会计师事务所开展审计业务。公司控股股东、实际控制 人不得在公司董事会、股东大会审议前，向公司指定会计师事务所，不得干预审 计委员会独立履行审核职 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-025 北京义翘神州科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次会计政策变更是公司根据法律法规和国家统一的会计制度的要求进 行的变更，不会对公司财务状况、经营成果和现金流量产生重大影响。 2、根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等相关规定，本次会计政策变更无需提交公司董事会和股东大会审 议。 北京义翘神州科技股份有限公司（以下简称"公司"）根据中华人民共和国 财政部（以下简称"财政部"）发布的《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2022〕31 号）（以下简称"《准则解释第 16 号》"）的要求 变更会计政策。本次会计政策变更具体情况如下： 一、本次会计政策变更概述 1、会计政策变更的原因 2022 年 11 月 30 日，财政部发布了《准则解释第 16 号》，规定了"关于单 项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"的 内容，自 2023 ...

北京义翘神州科技股份有限公司 2023 年度内部控制自我评价报告 北京义翘神州科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合北京义翘神州科技股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告基准日） 的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实、准确、完整，提高经营效率和效果，促进实现发展战略。由于内 部控制存在的固有局限性，故仅能为实现上述目标提供合理保证 ...

北京义翘神州科技股份有限公司 独立董事 2023 年度述职报告 均投赞成票，并与其他独立董事共同发表了关于公司第一届董事会第二十二次 会议相关事项的独立意见，无提出异议的事项，亦不存在反对、弃权的情形。 本人谨慎、认真地行使了公司所赋予独立董事的权利。 （泮伟江） 各位股东及股东代表： 本人（泮伟江）作为北京义翘神州科技股份有限公司（以下简称"公 司"、"义翘神州"）第一届董事会独立董事，在 2023 年 1 月 1 日至 2023 年 3 月 23 日任期内，严格按照《公司法》《证券法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律法规和规范性文件以及《公司章程》《独立董事工作制 度》等规定和要求，切实履行独立董事职责，维护公司及股东的合法权益。现 将本人 2023 年度任期内工作情况报告如下： 一、基本情况 本人泮伟江，1979 年出生，中国国籍，无境外永久居留权，2009 年毕业于 清华大学法学理论专业，获博士学位。2009 年 7 月至今就职于北京航空航天大 学，现任法学院副院长、教授、博士生导师，兼任中国科协-北京航空航天大学 ...

北京义翘神州科技股份有限公司 内部控制鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 内部控制鉴证报告 北京义翘神州科技股份有限公司 2023 年度内部控制自我评价报告 1-9 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制鉴证报告 致同专字（2024）第 110A009199 号 北京义翘神州科技股份有限公司全体股东： 我们接受委托，鉴证了北京义翘神州科技股份有限公司（以下简称义翘 神州）董事会对 2023 年 12 月 31 日与财务报表相关的内部控制有效性的认定。 义翘神州公司董事会的责任是按照《企业内部控制基本规范》建立健全内部 控制并保持其有效性，并确保后附的义翘神州《北京义翘神州科技股份有限 公司 2023 年度内部控制自我评价报告》真实、完整地反映义翘神州 2023 年 12 月 31 日与财务报表相关的内部控制。我们的责任是对义翘神州 2023 年 12 月 31 日与财务报表相关的内部控制有效性提出 ...

Financial Performance - The company's revenue for 2023 reached $42 million, reflecting a 15% year-over-year growth[1] - Future earnings guidance projects a 12% increase in revenue for 2024, aiming for $47 million[1] - Revenue in 2023 increased by 12.49% to RMB 646,388,500.38 compared to the adjusted revenue of RMB 574,603,390.32 in 2022[136] - Net profit attributable to shareholders decreased by 14.14% to RMB 260,131,747.68 in 2023 from the adjusted RMB 302,957,765.12 in 2022[136] - Net cash flow from operating activities increased by 29.34% to RMB 322,564,042.97 in 2023 compared to RMB 249,394,581.96 in 2022[136] - Basic earnings per share decreased by 24.31% to RMB 2.0134 in 2023 from the adjusted RMB 2.6599 in 2022[136] - Weighted average return on equity decreased by 0.63% to 4.11% in 2023 from 4.74% in 2022[136] - Non-recurring gains and losses in 2023 amounted to RMB 91,975,021.51, including RMB 100,320,770.68 from financial asset and liability transactions[141] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[1] - The company has secured $10 million in funding for its expansion into the European market[10] - The company has established subsidiaries in the US, Europe, and Japan, and continues to strengthen local service capabilities[148] - The company plans to acquire 100% equity of SCB for no more than $48 million to enhance product line coverage and sales potential in North America[188] - The company's market expansion capabilities are continuously improving, with ongoing expansion of customer service, technical support, and sales teams both domestically and internationally to provide timely and high-quality services[200] Research and Development - New product development is underway, with a focus on monoclonal antibodies, expected to launch in Q4 2024[2] - The company has completed the acquisition of a biotech firm in Suzhou, enhancing its R&D capabilities[3] - The company has invested $5 million in new technology research, particularly in gene editing[5] - A new strategy involves forming strategic partnerships with academic institutions to accelerate innovation[6] - The company's R&D team has grown by 25%, now comprising 150 researchers[9] Corporate Governance and Leadership - The company has established a Board Nomination and Remuneration Committee to research and review the remuneration of directors and senior management, formulate remuneration plans, conduct annual performance evaluations, and submit them to the Board for approval[20] - The company's directors and senior management have diverse roles across multiple organizations, including positions such as Chairman, General Manager, and Independent Director in various companies[13][16][19] - The company's directors and senior management have tenure periods ranging from 2015 to 2025, with some positions having no specified end date[13][16][19] - The company's directors and senior management are involved in various industries, including biotechnology, pharmaceuticals, and investment management[13][16][19] - The company's directors and senior management have international experience, with some holding positions in companies such as AuKing Mining Limited and Abbisko Cayman Limited[19] - The company's directors and senior management have academic backgrounds, with some holding positions such as Professor and Doctoral Supervisor at Beijing University of Chemical Technology[19] - The company's directors and senior management have no recent penalties from securities regulatory authorities in the past three years[19] - Total pre-tax compensation for directors, supervisors, and senior management in 2023 was 6.6657 million yuan, with the highest compensation of 2.7408 million yuan for Zhang Jie, the director, general manager, and R&D director[25] - The company's directors actively participated in the company's decision-making process and provided valuable professional advice on corporate governance and internal control systems[110] - The company's directors did not raise any objections to company matters during the reporting period[107] - The company's directors' suggestions were adopted, contributing to the improvement of the company's supervisory mechanisms and the protection of shareholders' rights[110] Employee and Talent Management - The company has 953 employees, including 67 with doctoral degrees, 218 with master's degrees, and 470 with bachelor's degrees[29] - The company adheres to a "people-oriented" talent philosophy, strictly complies with labor laws, and establishes a comprehensive employee management and welfare system[53] - For other employees, the company's human resources department is responsible for formulating salary plans, organizing performance evaluations, and determining employee compensation schemes, which are then reviewed and approved by the relevant leadership[20] Environmental and Social Responsibility - The company strictly complies with environmental protection laws and regulations, and no major environmental accidents occurred during the reporting period[35] - The company actively promotes energy conservation and emission reduction, continuously reduces resource consumption, and strengthens environmental factor control[36] - The company has established a risk assessment report for environmental emergencies and conducts regular drills to mitigate impacts[64] - The company has not engaged in poverty alleviation or rural revitalization work during the reporting period[50] Product and Service Development - The company's main business is providing biological reagent products and technical services for life science research and drug development[143] - The company has established multiple product lines including proteins, antibodies, kits, and culture media, offering tens of thousands of products[170] - The company's main business includes the development, production, and sales of biological reagents such as recombinant proteins, antibodies, genes, and culture media, as well as services like recombinant protein and antibody development and bioanalytical testing[197] - The production scheduling is managed by the production center, which formulates annual and monthly production plans based on market demand, marginal costs, and safety stock, and dynamically adjusts according to order situations[198] Financial and Operational Metrics - Total revenue for R&D services reached 630.95 million yuan, with a gross margin of 82.27%, representing a 9.81% YoY increase[191] - Revenue from recombinant proteins was 255.56 million yuan, with a gross margin of 87.67%, down 2.02% YoY[191] - Antibody revenue reached 181.11 million yuan, with a gross margin of 88.68%, up 8.99% YoY[191] - CRO service revenue was 154.05 million yuan, with a gross margin of 69.62%, up 40.49% YoY[191] - Domestic revenue was 245.27 million yuan, with a gross margin of 76.85%, up 9.02% YoY[191] - Overseas revenue reached 401.11 million yuan, with a gross margin of 85.24%, up 14.73% YoY[191] Corporate Commitments and Policies - The company's actual controller, Xie Liangzhi, commits to holding the company's shares for a long term, believing that the IPO is a financing tool rather than a short-term speculative activity[45] - Xie Liangzhi will consider reducing his holdings based on capital needs and investment arrangements, adhering to legal and regulatory requirements, and ensuring the stock price is above the IPO price or the latest net asset value per share[45] - The company's cash dividend distribution policy varies based on its development stage: 80% for mature stages without major capital expenditures, 40% for mature stages with major capital expenditures, and 20% for growth stages with major capital expenditures[46] - The company's profit distribution plan is proposed by management and the board, reviewed by the board, and approved by the general meeting of shareholders, with independent directors able to submit proposals directly to the board[46] - The company's actual controller commits to avoiding competition and related transactions with the company and its controlled entities, ensuring long-term compliance[48] - The company's dividend distribution policy focuses on long-term, sustainable development, balancing shareholder returns with the company's actual operations and future growth[56] - The company ensures independence from Shenzhou Cell and its subsidiaries in terms of assets, personnel, finance, organization, and business, complying with regulatory requirements[58] - The company minimizes related-party transactions with Shenzhou Cell and ensures fairness and reasonableness in pricing for necessary transactions[58] - The company commits to not occupying funds or assets of Shenzhou Cell and its subsidiaries through loans, debt repayment, or other means[58] - The company's controlling shareholder, Lhasa Ailik Investment Consulting Co., Ltd., has committed to not transferring or entrusting others to manage its shares for 36 months after the company's stock is listed on the stock exchange[75] - The company's actual controller, Xie Liangzhi, has committed to not transferring or entrusting others to manage his shares for 36 months after the company's stock is listed on the stock exchange[75] - Lhasa Ailik Investment Consulting Co., Ltd. has committed to not reducing its holdings of the company's shares if the company's stock price falls below the issue price for 20 consecutive trading days within six months of listing[75] - Xie Liangzhi has committed to not reducing his holdings of the company's shares if the company's stock price falls below the issue price for 20 consecutive trading days within six months of listing[75] - Lhasa Ailik Investment Consulting Co., Ltd. has committed to not reducing its holdings of the company's shares if the company is involved in major illegal activities that trigger mandatory delisting[75] - Xie Liangzhi has committed to not reducing his holdings of the company's shares if the company is involved in major illegal activities that trigger mandatory delisting[75] - Lhasa Ailik Investment Consulting Co., Ltd. has committed to not reducing its holdings of the company's shares if the company's stock price falls below the issue price for 20 consecutive trading days within six months of listing[76] - QM92 Limited and other entities have committed to long-term holding of the company's shares, indicating strong confidence in the company's future and industry prospects[78] - The company plans to use cash dividends as the primary method for profit distribution, with stock dividends considered based on growth and EPS dilution factors[80] - Cash dividends will be distributed annually if conditions are met, with interim cash distributions possible based on profitability and cash flow needs[80] - The company will implement differentiated cash dividend policies considering industry characteristics, development stage, and capital expenditure plans[80] - Lhasa Ailik Investment Consulting Co., Ltd. has committed to avoiding unfair competition and ensuring fair pricing in related-party transactions[82] - The company's actual controller, Xie Liangzhi, has pledged to avoid any business that competes with the company's main operations[86] - Xie Liangzhi has also committed to not providing any form of assistance to competitors, including financial, business, or technical support[86] - The company will adjust its business scope to avoid conflicts with the main operations of its subsidiaries[86] - The company will ensure that any related-party transactions follow market-based pricing principles[86] - The company will maintain transparency and fairness in all business dealings, adhering to legal and regulatory requirements[86] - The company's controlling shareholder, Lhasa Ailik, has issued a commitment to avoid同业竞争, ensuring no competitive business operations with the company's main business[87] - The company has established a three-year stock price stabilization plan post-IPO, effective from August 16, 2021, to August 15, 2024, to maintain stock price stability[88] - The company's actual controller, Xie Liangzhi, has committed to the accuracy and completeness of the prospectus and will bear legal responsibility for any重大信息披露违法[92] - The company's actual controller, Xie Liangzhi, committed to bearing all losses and expenses incurred by the company due to any disputes or penalties related to social insurance and housing provident funds[98] - The company's directors and senior management committed to not using company assets for personal investments or consumption unrelated to their duties[98] - The company's controlling shareholder, Lhasa Ailik Investment Consulting Co., Ltd., made commitments to safeguard the interests of public investors[98] Board and Committee Activities - The company held 4 board meetings in 2023, including the 22nd, 23rd, and 1st and 2nd meetings of the second board of directors[26] - The company held its second board meeting on October 19, 2023, and approved the "Proposal on the Acquisition of Equity in an Overseas Company"[106] - The company's second board meeting on August 25, 2023, approved the "2023 Semi-Annual Report and its Summary" and the "Special Report on the Storage and Use of Raised Funds for the First Half of 2023"[106] - The company's second board meeting on May 25, 2023, approved the "Proposal on Signing a Lease Agreement and Related Party Transactions"[106] - The company's second board meeting on April 25, 2023, approved the "2023 First Quarter Report"[106] - The company's strategic committee held 3 meetings in 2023, approving key proposals including the election of the second board's strategic committee chairman and the acquisition of overseas company equity[111] - The company's audit committee held 5 meetings in 2023, reviewing and approving the 2022 annual report, financial report, and the 2023 first-quarter report[111] - The company's board of directors held 9 meetings in 2023, with all directors attending, ensuring the accuracy and completeness of the annual financial report[126] Industry and Market Context - The company's industry, focused on biological reagents and technical services, is closely tied to basic scientific research and the biopharmaceutical industry, with strong demand and low cyclicality[129] - Global bio-reagent market size grew from $15 billion in 2017 to $20.9 billion in 2021, with a CAGR of 8.6%[168] - The company has established subsidiaries in the US, Europe, and Japan, with products sold in over 90 countries and regions, serving more than 9,000 customers[180] - The company faces high barriers to entry due to the need for specialized human resources and technical expertise in the biological reagent industry[151] Subsidiary and Operational Achievements - Suzhou subsidiary has successfully passed CMA and CNAS certifications, enabling it to issue authoritative testing reports and meet dual reporting requirements for both domestic and international markets[71] - Taizhou subsidiary has made steady progress in recombinant expression services, antibody development, and CRO services, with liquid media achieving large-scale production and dry powder media completing formula finalization and quality standard establishment[71] - The company has established a comprehensive safety management system, including an EHS department, employee safety training, provision of necessary protective equipment, and regular safety inspections[72] Accounting and Financial Reporting - The company implemented new accounting standards effective January 1, 2023, with minimal impact on financial statements[137] - The company's profit distribution plan for 2022 was approved, with a base of 127,760,391 shares, distributing a cash dividend of 20.00 yuan per 10 shares (tax included), and no stock dividends or capital reserve transfers[133] Public Relations and Communication - The company actively builds harmonious public relations and maintains transparent communication with government, media, regulatory bodies, and the public[68] - The company adheres to the principle of honesty and trustworthiness, builds long-term strategic partnerships with suppliers and customers, and ensures product safety and quality[41] - The company adheres to the principle of independent development, aiming to provide high-quality reagents and services for global life science research and biopharmaceutical innovation[66]

北京义翘神州科技股份有限公司 第二条 公司的重大投资应遵循的基本原则：遵守国家法律、法规，符合国 家产业政策；符合公司发展战略和中长期发展规划，合理配置公司资源，创造良 好经济效益；注重风险防范，保证资金的安全运行。 第三条 本制度适用于公司及其所属的全资子公司、控股子公司（以下统称 "子公司"）的一切对外投资行为。 第四条 本制度所称的对外投资是指公司为获取未来收益而将一定数量的货 币资金、股权或者经评估后的实物或无形资产作价出资，对外进行各种形式的投 资活动，含委托理财、对子公司投资等，设立或者增资全资子公司除外。 按照投资期限的长短，公司对外投资分为短期投资和长期投资。短期投资主 要指公司购入能够随时变现且持有时间不超过一年（含一年）的投资，包括上市 公司股票、债券、基金、外汇等交易性金融资产。长期投资主要指投资期限超过 一年，或不能随时变现或不准备变现的各种投资，包括股权投资等。 第五条 根据国家对投资行为管理的有关要求，投资项目需要报政府部门审 批的，应履行必要的报批手续，保证公司各项投资行为的合法合规性，符合国家 宏观经济政策。 第六条 公司对外提供担保事项按照公司对外担保管理制度执行。投资事项 ...